Max Ostermeier is CEO of Implandata
Implandata is going to transform the management of glaucoma patients.
80 million patients are at risk of permanent loss of eyesight because of glaucoma. Management of glaucoma patients is primarily eye center based. Disease status and progression is unknown in between office visits, resulting in irreversible vision loss at a significant number of patients.
Implandata’s breakthrough EYEMATE system introduces remote management and care of glaucoma. Crucial disease parameters are collected at the patient, AI analyzed and provided real-time to the ophthalmologist, enabling personalized therapy guidance.
During this Podcast episode, Ben sits down with Max to discuss how Implandata began, how the cutting edge tech works, how to successfully get a product out to market from scratch and the future of tech and data-driven healthcare.
Venturi's Voice: Technology | Leadership | Staffing | Career | Innovation